[go: up one dir, main page]

UY23718A1 - Procedimiento para la preparacion de derivados de octahidro- fenantreno - Google Patents

Procedimiento para la preparacion de derivados de octahidro- fenantreno

Info

Publication number
UY23718A1
UY23718A1 UY23718A UY23718A UY23718A1 UY 23718 A1 UY23718 A1 UY 23718A1 UY 23718 A UY23718 A UY 23718A UY 23718 A UY23718 A UY 23718A UY 23718 A1 UY23718 A1 UY 23718A1
Authority
UY
Uruguay
Prior art keywords
signifies
signify
preparation
octahydro
amino
Prior art date
Application number
UY23718A
Other languages
English (en)
Inventor
Thierry Godel
Eva-Maria Gutknecht
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY23718A1 publication Critical patent/UY23718A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/52—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/70—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a un procedimiento para la preparación de derivados de octahidro-fenantreno tricíclicos de fómula general (I), en donde: R1 y R2 significan cada uno individualmente H o alquilo; R4 y R5 ambos significan H o ambos significan halógeno o uno significa H y el otro significa halógeno, hidroxilo, alcoxilo, ariloxilo o amino y R3 significa H o, cuando no está/están presente(s) grupo(s) amino primario(s) o secundario(s), alcanoilo; así como sales farmacéuticamente utilizables de compuestos de fórmula (I) con ácidos tiene valiosas propiedades farmacodinámicas como antagonistas de NMDA no competitivos y pueden utilizarse, por consiguiente como neuroprotectores. Ej. no limitante: rac-cis-4b-(2-amino-etil)-4b,5,6,7,8,8a,9,10-octahidro-fenantren-3,8a-diol
UY23718A 1993-01-15 1994-01-14 Procedimiento para la preparacion de derivados de octahidro- fenantreno UY23718A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH12393 1993-01-15

Publications (1)

Publication Number Publication Date
UY23718A1 true UY23718A1 (es) 1994-07-06

Family

ID=4179785

Family Applications (1)

Application Number Title Priority Date Filing Date
UY23718A UY23718A1 (es) 1993-01-15 1994-01-14 Procedimiento para la preparacion de derivados de octahidro- fenantreno

Country Status (22)

Country Link
US (1) US5385947A (es)
EP (1) EP0606661B1 (es)
JP (1) JP2505978B2 (es)
KR (1) KR940018355A (es)
CN (1) CN1097727A (es)
AT (1) ATE150001T1 (es)
AU (1) AU668442B2 (es)
BR (1) BR9400082A (es)
CA (1) CA2111138A1 (es)
CZ (1) CZ8694A3 (es)
DE (1) DE59305763D1 (es)
DK (1) DK0606661T3 (es)
ES (1) ES2099362T3 (es)
FI (1) FI940147L (es)
GR (1) GR3023581T3 (es)
HU (1) HUT69688A (es)
IL (1) IL108307A0 (es)
NO (1) NO180630C (es)
NZ (1) NZ250652A (es)
PL (1) PL301905A1 (es)
UY (1) UY23718A1 (es)
ZA (1) ZA94103B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684553B2 (en) * 1993-10-13 1997-12-18 Otsuka Pharmaceutical Co., Ltd. Nitrogen monoxide synthesis inhibitor
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5859001A (en) * 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
US6197833B1 (en) 1995-07-24 2001-03-06 Apollo Biopharmaceutics, Inc. Neuroprotective effects of polycyclic phenolic compounds
JPH11510144A (ja) * 1995-07-24 1999-09-07 ユニバーシティー・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド 細胞に神経保護を付与するための薬剤の製造のための非エストロゲン多環式フェノール化合物の使用
WO2001041707A2 (en) 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
DE60112624T2 (de) * 2001-01-04 2006-06-08 Karo Bio Ab Östrogenrezeptor-Liganden und Verfahren
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory PH VALVE DEPENDENT NMDA RECEPTOR ANTAGONISTS
DE10140213A1 (de) * 2001-08-16 2003-02-27 Gruenenthal Gmbh Substituierte Octahydrophenanthren-Verbindungen
DE102004015921B4 (de) 2004-03-31 2006-06-14 Infineon Technologies Ag Rückwärts sperrendes Halbleiterbauelement mit Ladungskompensation
CN101180302B (zh) * 2005-05-25 2013-06-19 詹森药业有限公司 制备(αS,βR)-6-溴-α-[2-(二甲基氨基)乙基]-2-甲氧基-α-1-萘基-β-苯基-3-喹啉乙醇的方法
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
JP2010532382A (ja) * 2007-06-29 2010-10-07 エモリー・ユニバーシテイ 神経保護のためのｎｍｄａ受容体拮抗薬
US20120238549A1 (en) * 2011-03-15 2012-09-20 Abbott Laboratories Nuclear Hormone Receptor Modulators
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
CZ305733B6 (cs) * 2014-08-26 2016-02-24 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Amfifilní sloučeniny s neuroprotektivními účinky

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317910A (en) * 1978-03-20 1982-03-02 E. R. Squibb & Sons, Inc. Benzo-cyclitolamines
US5071853A (en) * 1989-03-23 1991-12-10 Bigge Christopher F Polycyclic amines useful as cerebrovascular agents
US5180736A (en) * 1989-03-23 1993-01-19 Warner-Lambert Company Polycyclic amines useful as cerebrovascular agents

Also Published As

Publication number Publication date
HU9400056D0 (en) 1994-05-30
JP2505978B2 (ja) 1996-06-12
FI940147A7 (fi) 1994-07-16
NO180630B (no) 1997-02-10
EP0606661A1 (de) 1994-07-20
CZ8694A3 (en) 1994-08-17
FI940147L (fi) 1994-07-16
NO940143L (no) 1994-07-18
GR3023581T3 (en) 1997-08-29
US5385947A (en) 1995-01-31
CN1097727A (zh) 1995-01-25
ZA94103B (en) 1994-08-19
FI940147A0 (fi) 1994-01-12
ES2099362T3 (es) 1997-05-16
EP0606661B1 (de) 1997-03-12
NO940143D0 (no) 1994-01-14
BR9400082A (pt) 1994-08-02
PL301905A1 (en) 1994-07-25
DK0606661T3 (da) 1997-09-01
DE59305763D1 (de) 1997-04-17
NZ250652A (en) 1995-10-26
AU5311494A (en) 1994-07-21
NO180630C (no) 1997-05-21
HUT69688A (en) 1995-09-28
AU668442B2 (en) 1996-05-02
ATE150001T1 (de) 1997-03-15
CA2111138A1 (en) 1994-07-16
KR940018355A (ko) 1994-08-16
JPH06234711A (ja) 1994-08-23
IL108307A0 (en) 1994-04-12

Similar Documents

Publication Publication Date Title
UY23718A1 (es) Procedimiento para la preparacion de derivados de octahidro- fenantreno
ES2134926T3 (es) Derivados vinileno-azaindolicos y su procedimiento de preparacion.
ES2055056T3 (es) Derivados de pirimidopirimidina.
AR248138A1 (es) Un procedimiento de preparacion de acilamino-2-tiazoles.
MX9404885A (es) Derivados de ariliden y heteroariliden oxindoles, proceso para supreparacion y composiciones farmaceuticas que los contienen.
ES2117155T3 (es) Nuevas 3,3-difenilpropilaminas, su uso y su preparacion.
ES464136A1 (es) Procedimiento para la preparacion de derivados de quinazolo-na.
ES2055035T3 (es) Un proceso para la preparacion de un glicosido de antraciclina.
ES8106291A1 (es) Procedimiento para preparar derivados de 3-aminoproxiarilo
ES2061580T3 (es) Compuestos de 3,7-diazabiciclo(3,3,1)nonano, asi como procedimiento para su preparacion y medicamentos que contienen estos compuestos.
ES2191963T3 (es) Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos.
AR009572A1 (es) Derivados de 3,4,5,6,7,8-hexahidro pirido (4',3':4,5) tieno (2,3-d) pirimidina sustituidos en posicion 3 y su uso
ES470787A1 (es) Procedimiento para preparar derivados de benzoquinolicina
MX9504895A (es) Derivados de beta-aril- y beta-heteroaril-alfa- cianoacrilamida n-substituidos y proceso para su preparacion.
SE7501365L (es)
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
AR004691A1 (es) Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion
ES472290A1 (es) Un procedimiento para preparar un compuesto de benceno di- sustituido en orto
ECSP941050A (es) Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contiene
ES2038700T3 (es) Procedimiento para la obtencion de alilmercaptoacetil-sidnoniminas.
BR0214488A (pt) Derivados de benzotiazol
ES2065723T3 (es) Derivados de carbostirilo y composiciones que los contienen para su uso como agentes de mejora de trastornos de la conciencia, estimulantes del sistema nervioso central o agonistas de receptores sigma.
ES2119752T3 (es) 5-amino-5,6,7,8-tetrahidroquinolinas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos.
ES470751A1 (es) Procedimiento de preparacion de nuevas piridazinilhidrazonasy de sus sales farmaceuticamente aceptables